September, 2014

1. Clinical Trial Office: Support service for clinical trials performed using BMC clinical infrastructure September, 2014

2. Executive Summary A new clinical research support service is being launched to provide a central and comprehensive framework of financial and administrative support and oversight for clinical trials performed using BMC clinical infrastructure. The objectives of the service are to: Increase the support for clinical trials through expanded institutional involvement and continued investments in the clinical research infrastructure Improve cost recoveryby expanding on our ability to budget and bill industry-sponsored clinical research for professional fees and hospital service costs Enhance clinical research billing processesby educating the clinical research community on national best practices; and implementing policies, procedures and systems The Clinical Trial Office is a major component of this new environment and will be involved with awards for both BU and BMC. This presentation will outlinewhy changes are necessary, what’s new (focus on the Clinical Trial Office), what has been done so far, and next steps.

3. Why is Change Necessary? The National landscape consists of tighter regulations and increased scrutiny of research costs. Noncompliance with federal regulations can lead to stringent corrective action plans and financial implications. A few examples: • University of Alabama at Birmingham (2005) $3.4M • Unlawfully billed Medicare for clinical research trials that were also billed to the sponsor of research grants (double billing). • Rush University Medical Center in Chicago (2005) $1.0M • Inappropriate clinical trials charges submitted to Medicare and Medicaid • Beth Israel Deaconess Medical Center (2002) $ 3.2M • Improper billing of experimental cardiac devices to Medicare The following examples at BMC were identified in the recent past: • Clinical Trial participants received bills in error due to incorrect registration • Potential misappropriation of clinical trial expenses resulting in return of funds • A Clinical Trial requiring Research MRI’s did not follow standard practice and could have resulted in research charges being charged incorrectly • An independent assessment of 5 clinical trials in 2012 found that 89% of expected professional charges related to participant study visits were potentially unbilled.

4. Institutional Commitment to Clinical Research:Creating a Clinical Research Identity Being recruited to support the strategic direction of clinical research at BMC and provide clinical and scientific support to Principal Investigators and the central service functions that support clinical research Membership: Chief Medical Officer (Ravin Davidoff, MD), Chief Financial Officer (Richard Silveria), Vice President, Finance (John Lindstedt), Medical Director, Research (Recruiting), Exec. Director, Research (Michael Collins) Hired to bring management to the various Research Operation Functions Being formed and will include senior faculty across BMC participating in research Membership: A mix of BMC departmental administrators and clinical research coordinators, as well as representation from Patient Financial Services, Revenue Integrity, Investigational Pharmacy, and Radiology Supports clinical research by managing the financial, legal and administrative components of clinical trials in conjunction with Principal Investigators and Study Teams

5. A New Value Added Service for Research MANAGE | USE BU Charles River Campus Human Research Protection Program (IRB): BUMC BU Medical Campus Boston Medical Center Clinical and Translational Science Award: BUMC Office of Research Compliance: CRC Intellectual Property and Commercial Ventures: CRC Laboratory for Animal Science Center: BUMC Investigational Pharmacy Service: BMC Clinical Trial Office: BMC Effective: 2014 Note: Excludes research operations managed separately

6. Clinical Trial Office Support Services The Clinical Trial Office (CTO) will support clinical research by managing the financial, legal and administrative components of clinical trials in conjunction with Principal Investigators (PIs) and Study Teams. • The CTO is involved in the following functions: • Study Initiation • Medicare Coverage Analysis (MCA) • Budget Development (comprehensive negotiation support) • Negotiation of Contract Terms and Conditions • Financial and Billing Management • Reporting and Auditing • Account Reconciliation and Closeout • The new program leverages best practices from peer institutions, including Partners Healthcare, Beth Israel Deaconess Medical Center, Tufts Medical Center, and Children’s Hospital. In addition to the local peer review; Jim Moran, Executive Director, Healthcare Advisory Services at Ernst & Young (formerly of Washington University) and Erika Stevens, Senior Manager (formerly of Dartmouth Hitchcock Medical Center and Columbia University Medical Center) are contributing insight to ensure that the CTO is consistent with standard practices.

7. Benefits of CTO Support Service

8. PI Engagement is Important for Success! Although the CTO will strive to minimize additional administrative burdens on Principal Investigators, increased participation is needed to ensure the continued success of the institution’s clinical research program.

9. CTO Recruitment • Director, Clinical Trial Office: Selvin Ohene • Formerly Administrative Director of Cancer Center, Tufts Medical Center • Senior Clinical Trial Financial Analyst: Dean Robinson • Formerly Clinical Trial Financial Analyst, Massachusetts General Hospital (CCPO) • Senior Clinical Trial Financial Analyst: Allisson Dugan • Formerly Senior Research Administrator, Beth Israel Deaconess Medical Center • Clinical Research Attorney: Meghan Garland • Formerly Senior Agreement Associate, Partners Healthcare

10. VelosCT • Boston Medical Center has made a capital investment ($600K+) to implement a fully functional clinical trial management system (VeloseResearch) that will assist with: • Participant recruitment and accrual • Scheduling, follow-up, retention and management • Financial management • Reporting for all clinical trials • The implementation will be staged in three main phases, involve stakeholders with various cross-functioning subject matter expertise, and external support and is expected to be complete May, 2015 . • Phase I: System setup, configuration and onboarding new trials • Phase II: Data migration of selected existing studies • Phase III: Additional interfaces created and integrated over next three years • Executive Sponsor: Michael Collins: Executive Director, Research • Project Manager: Garo Stone-DerHagopian: Associate Director, Research Business Intelligence

11. Appendix

12. RESEARCH vs. SOC CHARGE CAPTURE BILLING & CODING CLAIMS EDITING PATIENT VISIT PATIENT REGISTRATION INVOICING COLLECTIONS PATIENT CONSENT POST TO CORRECT RESEARCH ACCT. COVERAGE ANALYSIS IRB APPROVAL Clinical Trial Finance Lifecycle CTO INVOLVEMENT RECONCILIATION BUDGETS CONTRACT MGMT REPORTING ACCOUNT CLOSEOUT

13. Policies and Procedures (Ernst & Young Engagement) E&Y Advisory Services reviewed 35 policies and procedures (some in draft). Minimal or no edits were suggested for 27 policies with proposed edits to 8 policies. E&Y drafted an additional 20 policies to support research operations.

14. Training and Educational Opportunities Time commitment is expected to be 1 hour per topic area. • The CTO will work in collaboration with the Associate Director, Research Operations to provide the clinical research community with opportunities for training and education. • There will be multiple channels available to PIs and their study teams to receive training: • Live group training sessions (available in Fall, 2014) • Targeted online training (via Healthstream) (TBA) • Seminar series (TBA) • The following training sessions will be required for Investigators/study teams involved in clinical research: